Hair Loss Treatment Linked to Increased Suicide Risk

Summary of the Article: Finasteride and mental Health Risks

This article details a growing concern regarding the potential link between finasteride, a common drug used to treat male pattern hair loss and benign prostatic hyperplasia (BPH), and increased risks of mood disorders and suicidal thoughts.

Key Findings & Concerns:

* Increased Risk: A recent literature review of eight studies (2017-2023) suggests a considerably higher risk of mood disorders and suicidal thoughts in people taking finasteride compared to those who don’t.
* Long-Standing Concerns: Concerns about finasteride’s impact on mood have existed for years, but have been largely overlooked by manufacturers and regulatory bodies.
* FDA Acknowledgment & Delayed Action: The FDA acknowledged depression as a potential side effect in 2011 and suicidality in 2022, but internal documents reveal recommendations to add “suicidal thoughts and behavior” to the warning label were rejected as early as 2010.
* Underreporting & Systemic Failure: The article argues that reported suicide numbers associated with finasteride are likely vastly underestimated, not due to simple underreporting, but due to a “systemic failure of pharmacovigilance.”
* Lack of Research: The original manufacturer, Merck, is criticized for not conducting adequate safety research, and regulators for not requiring it.
* Call for transparency: The author, Mayer Brezis, emphasizes the need for transparency regarding the conflict between innovation and public safety.

In essence, the article presents a critical look at the potential mental health risks associated with finasteride, arguing that these risks have been downplayed for too long and require greater attention and investigation.